<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920214</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1010</org_study_id>
    <nct_id>NCT04920214</nct_id>
  </id_info>
  <brief_title>Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCC</brief_title>
  <official_title>Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Third Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Jining No.1 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Red Cross Hospital, Hangzhou, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengjing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, there are few studies on the diagnostic ability of CEUS-LI-RADS in patients with&#xD;
      non-high risk factors for liver nodules. Whether this classification is applicable to such&#xD;
      patients remains controversial. There are relatively few studies on the diagnostic efficacy&#xD;
      of HCC in clinical diagnosis and the consistency between map readers, and the applicable&#xD;
      population is only focused on patients with hepatic fibrosis. Therefore, this study explored&#xD;
      the application value of CEUS Li-RADS in liver focal lesions in patients with non-high risk&#xD;
      factors for hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the latest epidemiological survey in 2018, primary liver cancer is the sixth&#xD;
      most common cancer in the world. Among these, hepatocellular carcinoma is the most common&#xD;
      type of liver cancer. Clinicians' diagnosis of HCC has been gradually transformed from&#xD;
      invasive puncture diagnosis to non-invasive diagnosis based on enhanced imaging findings. In&#xD;
      HCC tissue, the number of small blood vessels was increased and the arrangement was&#xD;
      disordered. Compared with the surrounding normal liver tissue, there were more obvious&#xD;
      manifestations of increased arterial blood supply. Contrast-enhanced Ultrasound (CEUS) is the&#xD;
      most sensitive and objective tool for detecting circulatory perfusion, and can achieve a&#xD;
      clear and dynamic display of low speed and small blood flow. Its diagnostic efficacy of HCC&#xD;
      is similar to the diagnostic ability of Enhanced CT.&#xD;
&#xD;
      In order to better standardize the writing of liver CEUS report by sonographers, and to&#xD;
      facilitate sonographers and clinicians to reach a consensus on the diagnosis and treatment of&#xD;
      liver lesions, In 2017, the American Radiology College (ACR) released the CEUS-based Liver&#xD;
      Imaging Reporting and Data System (CEUS-Li-RADS). At the same time, according to the&#xD;
      perfusion methods in the arterial, portal and venous phases, the CEUS-Li-RADS angiographic&#xD;
      findings were classified into main features and LR-M features by ACR Association. The former&#xD;
      included high enhancement in arterial phase and mild clearance in portal vein phase (after&#xD;
      60S) or delayed phase. The latter includes annular high enhancement, early clearance and&#xD;
      complete clearance. In the classification, CEUS Li-RADS was classified into the following&#xD;
      categories according to the possibility of HCC diagnosis with different characteristics of&#xD;
      CEUS: LR-1 (definitely benign), LR-2 (possibly benign),LR-3 (possibly HCC), LR-4 (highly&#xD;
      suspected HCC), LR-5 (confirmed HCC), and LR-M (liver malignant lesion, not specifically&#xD;
      HCC).&#xD;
&#xD;
      In January 2018, Professor Bruix, Chairman of AASLD, wrote in the journal Heaptology that a&#xD;
      qualified LIRADS classification should meet the following requirements :(1) LIRADS&#xD;
      classification should focus on high-risk groups for HCC; (2) In LI-RADS classification, the&#xD;
      specificity of LR-5 in the diagnosis of HCC should be close to 100%; (3) There is a good&#xD;
      consistency between the main evaluation criteria of LI-RADS classification, LR-M evaluation&#xD;
      criteria and the readers of final classification.&#xD;
&#xD;
      Currently, there are few studies on the diagnostic ability of CEUS-LI-RADS in patients with&#xD;
      non-high risk factors for liver nodules. Whether this classification is applicable to such&#xD;
      patients remains controversial. There are relatively few studies on the diagnostic efficacy&#xD;
      of HCC in clinical diagnosis and the consistency between map readers, and the applicable&#xD;
      population is only focused on patients with hepatic fibrosis. Therefore, this study explored&#xD;
      the application value of CEUS Li-RADS in liver focal lesions in patients with non-high risk&#xD;
      factors for hepatocellular carcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positive Predictive Value</measure>
    <time_frame>3 years</time_frame>
    <description>The positive predictive value of LR-5 diagnosis of HCC was compared among different map readers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative Predictive Value</measure>
    <time_frame>3 years</time_frame>
    <description>The negative predictive value of LR-5 diagnosis of HCC was compared among different map readers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>3 years</time_frame>
    <description>The sensitivity of LR-5 diagnosis of HCC was compared among different map readers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>3 years</time_frame>
    <description>The specificity of LR-5 diagnosis of HCC was compared among different map readers</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <description>patients with hepatic focal lesions&#xD;
patients with non-high risk factors for hepatocellular carcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SonoVue</intervention_name>
    <description>CEUS examination was performed and corresponding image information of liver lesions was obtained.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. patients with focal liver lesions&#xD;
&#xD;
          2. patients with non-high risk factors for hepatocellular carcinoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient showed focal liver lesions on routine ultrasound examination.&#xD;
&#xD;
          -  Non-HCC high-risk patients (hepatitis B, cirrhosis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High-risk patients with HCC (hepatitis B, cirrhosis);&#xD;
&#xD;
          -  Patients with solid liver tumors could not be found by conventional imaging;&#xD;
&#xD;
          -  Patients who do not sign informed consent;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pintong Huang</last_name>
    <role>Study Chair</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pintong Huang</last_name>
    <phone>+8618857168333</phone>
    <email>huangpintong@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peile Jin</last_name>
    <phone>+8619883125285</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junhong Ren</last_name>
      <phone>13910813603</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina Tang</last_name>
      <phone>13625079386</phone>
    </contact>
    <contact_backup>
      <last_name>Yijie Chen</last_name>
      <phone>13960766160</phone>
      <email>19178610@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weidong Ren</last_name>
      <phone>18940251657</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Ningxia Medical University</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengrong Mi</last_name>
      <phone>13909599333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Jining No.1 People's Hospital</name>
      <address>
        <city>Jining</city>
        <state>Shandong</state>
        <zip>272000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Long Li</last_name>
      <email>weifanglilong@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qin Chen</last_name>
      <phone>18981838665</phone>
      <email>1718686103@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Third Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Jiang</last_name>
      <phone>13920111890</phone>
      <email>dr.jingxiang@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Ultrasound, Second Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pintong Huang, director</last_name>
      <phone>+8618857168333</phone>
      <email>huangpintong@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Peile Jin, collegue</last_name>
      <phone>+8619883125285</phone>
      <email>jinpeile@zju.edu.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Red Cross Hospital, Hangzhou, China</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Zhang</last_name>
      <email>zhangying5201@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Xu</last_name>
      <phone>13588341756</phone>
      <email>xudnj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Na Feng</last_name>
      <phone>15868808101</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 30, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver</keyword>
  <keyword>liver imaging</keyword>
  <keyword>liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

